CAR2 Anti-CEA CAR-T Cell (Sorrento Therapeutics)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameCAR2 Anti-CEA CAR-T Cell (Sorrento Therapeutics)
Drug Alias NameAnti CEA CAR T cell therapy(Sorrento Therapeutics)CAR2抗CEA CAR-T细胞-Sorrento TherapeuticsCAR2 Anti-CEA CAR-T cells (Sorrento Therapeutics)Anti-CEA CAR-TAnti-CEA T-cells +[13] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CEA
TargetsCarcinoembryonic antigen
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSorrento Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSorrento Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A